<b>Cambritaxestat</b><b> Reduces Tumor Growth</b> in mGC models

<p dir="ltr">The study confirmed the efficacy of therapy targeting the ATX/LPA axis in advanced GC. Cambritaxestat, an ATX inhibitor with oral bioavailability and tolerability, is a promising candidate for combination with standard chemotherapy or antiangiogenic therapies, helping to overcome resistance and adapt conventional strategies.</p>